European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

L. Gossec; J. S. Smolen; C. Gaujoux-Viala; Z. Ash; H. Marzo-Ortega; D. van der Heijde; O. FitzGerald; D. Aletaha; P. Balint; D. Boumpas; J. Braun; F. C. Breedveld; G. Burmester; J. D. Canete; M. de Wit; H. Dagfinrud; K. de Vlam; M. Dougados; P. Helliwell; A. Kavanaugh; T. K. Kvien; R. Landewe; T. Luger; M. Maccarone; D. McGonagle; N. McHugh; I. B. McInnes; C. Ritchlin; J. Sieper; P. P. Tak; G. Valesini; J. Vencovsky; K. L. Winthrop; A. Zink; P. Emery

doi:10.1136/annrheumdis-2011-200350

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

L. Gossec^*, J. S. Smolen, C. Gaujoux-Viala, Z. Ash, H. Marzo-Ortega, D. van der Heijde, O. FitzGerald, D. Aletaha, P. Balint, D. Boumpas, J. Braun, F. C. Breedveld, G. Burmester, J. D. Canete, M. de Wit, H. Dagfinrud, K. de Vlam, M. Dougados, P. Helliwell, A. KavanaughT. K. Kvien, R. Landewe, T. Luger, M. Maccarone, D. McGonagle, N. McHugh, I. B. McInnes, C. Ritchlin, J. Sieper, P. P. Tak, G. Valesini, J. Vencovsky, K. L. Winthrop, A. Zink, P. Emery

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Results Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. Conclusion These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.

Original language	English
Pages (from-to)	4-12
Journal	Annals of the Rheumatic Diseases
Volume	71
Issue number	1
DOIs	https://doi.org/10.1136/annrheumdis-2011-200350
Publication status	Published - Jan 2012

Access to Document

10.1136/annrheumdis-2011-200350

Cite this

Gossec, L., Smolen, J. S., Gaujoux-Viala, C., Ash, Z., Marzo-Ortega, H., van der Heijde, D., FitzGerald, O., Aletaha, D., Balint, P., Boumpas, D., Braun, J., Breedveld, F. C., Burmester, G., Canete, J. D., de Wit, M., Dagfinrud, H., de Vlam, K., Dougados, M., Helliwell, P., ... Emery, P. (2012). European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 71(1), 4-12. https://doi.org/10.1136/annrheumdis-2011-200350

@article{595795e054d349e085ad6f4eb823bf69,

title = "European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies",

abstract = "Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Results Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. Conclusion These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.",

author = "L. Gossec and Smolen, {J. S.} and C. Gaujoux-Viala and Z. Ash and H. Marzo-Ortega and {van der Heijde}, D. and O. FitzGerald and D. Aletaha and P. Balint and D. Boumpas and J. Braun and Breedveld, {F. C.} and G. Burmester and Canete, {J. D.} and {de Wit}, M. and H. Dagfinrud and {de Vlam}, K. and M. Dougados and P. Helliwell and A. Kavanaugh and Kvien, {T. K.} and R. Landewe and T. Luger and M. Maccarone and D. McGonagle and N. McHugh and McInnes, {I. B.} and C. Ritchlin and J. Sieper and Tak, {P. P.} and G. Valesini and J. Vencovsky and Winthrop, {K. L.} and A. Zink and P. Emery",

year = "2012",

month = jan,

doi = "10.1136/annrheumdis-2011-200350",

language = "English",

volume = "71",

pages = "4--12",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "1",

}

Gossec, L, Smolen, JS, Gaujoux-Viala, C, Ash, Z, Marzo-Ortega, H, van der Heijde, D, FitzGerald, O, Aletaha, D, Balint, P, Boumpas, D, Braun, J, Breedveld, FC, Burmester, G, Canete, JD, de Wit, M, Dagfinrud, H, de Vlam, K, Dougados, M, Helliwell, P, Kavanaugh, A, Kvien, TK, Landewe, R, Luger, T, Maccarone, M, McGonagle, D, McHugh, N, McInnes, IB, Ritchlin, C, Sieper, J, Tak, PP, Valesini, G, Vencovsky, J, Winthrop, KL, Zink, A & Emery, P 2012, 'European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies', Annals of the Rheumatic Diseases, vol. 71, no. 1, pp. 4-12. https://doi.org/10.1136/annrheumdis-2011-200350

TY - JOUR

T1 - European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

AU - Gossec, L.

AU - Smolen, J. S.

AU - Gaujoux-Viala, C.

AU - Ash, Z.

AU - Marzo-Ortega, H.

AU - van der Heijde, D.

AU - FitzGerald, O.

AU - Aletaha, D.

AU - Balint, P.

AU - Boumpas, D.

AU - Braun, J.

AU - Breedveld, F. C.

AU - Burmester, G.

AU - Canete, J. D.

AU - de Wit, M.

AU - Dagfinrud, H.

AU - de Vlam, K.

AU - Dougados, M.

AU - Helliwell, P.

AU - Kavanaugh, A.

AU - Kvien, T. K.

AU - Landewe, R.

AU - Luger, T.

AU - Maccarone, M.

AU - McGonagle, D.

AU - McHugh, N.

AU - McInnes, I. B.

AU - Ritchlin, C.

AU - Sieper, J.

AU - Tak, P. P.

AU - Valesini, G.

AU - Vencovsky, J.

AU - Winthrop, K. L.

AU - Zink, A.

AU - Emery, P.

PY - 2012/1

Y1 - 2012/1

N2 - Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Results Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. Conclusion These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.

AB - Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Results Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. Conclusion These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.

U2 - 10.1136/annrheumdis-2011-200350

DO - 10.1136/annrheumdis-2011-200350

M3 - Article

C2 - 21953336

SN - 0003-4967

VL - 71

SP - 4

EP - 12

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 1

ER -